| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Mudanpioside C does not have a well-defined single pharmacological target, as it is a natural monoterpenoid with complex biological activities. It is a component of peony plants, which are used in traditional Chinese medicine for their anti-inflammatory, analgesic, and immunomodulatory properties. Mudanpioside C may contribute to these effects, but its specific molecular targets have not been fully characterized. The compound's mechanisms of action may involve modulation of inflammatory pathways, antioxidant activity, or regulation of immune responses.
|
|---|---|
| ln Vitro |
Mudanpioside C does not possess significant pharmacological activity as a pure compound in typical in vitro assays, as it is a natural product with complex biological activities. Studies on Mudanpioside C typically involve evaluating its anti-inflammatory, antioxidant, or immunomodulatory effects in cellular models. However, detailed in vitro activity data for Mudanpioside C specifically are limited, as most studies focus on the peony plant extracts or other related compounds.
|
| ln Vivo |
In vivo activity of Mudanpioside C is related to its role as a component of peony plants, which are used in traditional Chinese medicine. Peony extracts have been shown to have anti-inflammatory, analgesic, and immunomodulatory effects in animal models and clinical studies. However, the specific in vivo effects of Mudanpioside C as an isolated compound have not been extensively characterized. Most studies focus on the plant extracts, which contain multiple compounds including Mudanpioside C.
|
| Enzyme Assay |
In vitro enzyme/receptor binding experiments for Mudanpioside C are not typical, as it is a natural product with complex biological activities rather than a well-defined pharmacologically active compound. Studies may involve measuring its antioxidant activity, anti-inflammatory effects, or immunomodulatory effects in cell-based assays. The compound can also be used as a reference standard in analytical chemistry for the identification and quantification of monoterpenoids in plant extracts. Its chemical properties are characterized using standard analytical methods such as HPLC and mass spectrometry.
|
| Cell Assay |
In vitro cellular experiments for Mudanpioside C typically involve studying its effects on inflammatory responses, oxidative stress, or immune function in cell lines. Cells are treated with the compound, and the production of inflammatory mediators, reactive oxygen species, or cytokines is measured. The compound's effects on cell viability and proliferation are also assessed. The anti-inflammatory, antioxidant, or immunomodulatory activities of Mudanpioside C are evaluated in these cellular models. However, detailed studies on Mudanpioside C specifically are limited.
|
| Animal Protocol |
In vivo animal experiments for Mudanpioside C are not typical, as it is a natural product component rather than a drug candidate. However, studies may involve administering peony extracts or their components to animals to evaluate their anti-inflammatory, analgesic, or immunomodulatory effects. The effects of Mudanpioside C as an individual compound have not been extensively studied in vivo.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Mudanpioside C have not been extensively characterized, as it is a natural product component rather than a drug candidate. With a molecular weight of 600.57 and complex glycoside structure, Mudanpioside C is expected to have poor oral bioavailability and may be poorly absorbed from the gastrointestinal tract. Detailed studies on its absorption, distribution, metabolism, and excretion are limited. Most pharmacokinetic studies focus on the plant extracts rather than the individual compounds.
|
| Toxicity/Toxicokinetics |
Toxicological data for Mudanpioside C are limited, as it is a natural product component rather than a drug candidate. Standard safety precautions for handling natural products apply, including the use of personal protective equipment and working in a well-ventilated area. The compound is not intended for human consumption. Its toxicity profile has not been extensively characterized.
|
| Additional Infomation |
Reports indicate that peony contains [(1R,2S,3S,5S,6R,8S)-3-[(2S,3R,4S,5S,6R)-6-(benzoyloxymethyl)-3,4,5-trihydroxyoxacyclohexane-2-yl]oxy-6-hydroxy-8-methyl-9,10-dioxacyclohexanetetracyclo[4.3.1.02,5.03,8]decane-2-yl]methyl4-hydroxybenzoic acid, and related data have been reported.
Mudanpioside C is a research compound that has not entered clinical trials or received regulatory approval for therapeutic use. It is a component of peony plants, which are used in traditional Chinese medicine for their anti-inflammatory, analgesic, and immunomodulatory properties. Mudanpioside C is used in research to study the pharmacological activities of monoterpenoids and to understand the active principles of traditional medicinal herbs. Further research is needed to fully elucidate its biological activities and potential therapeutic applications. |
| Molecular Formula |
C30H32O13
|
|---|---|
| Molecular Weight |
600.567290306091
|
| Exact Mass |
600.184
|
| CAS # |
172760-03-1
|
| PubChem CID |
11801727
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
789.1±60.0 °C at 760 mmHg
|
| Flash Point |
258.6±26.4 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.699
|
| LogP |
5.22
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
43
|
| Complexity |
1110
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@]12C[C@@]3([C@@H]4C[C@]1([C@@]4(C(O2)O3)COC(=O)C5=CC=CC=C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)COC(=O)C7=CC=C(C=C7)O)O)O)O)O
|
| InChi Key |
HMSMTLNPCAHHGP-IPRVBXPUSA-N
|
| InChi Code |
InChI=1S/C30H32O13/c1-27-13-29(37)19-11-30(27,28(19,26(42-27)43-29)14-39-24(36)15-5-3-2-4-6-15)41-25-22(34)21(33)20(32)18(40-25)12-38-23(35)16-7-9-17(31)10-8-16/h2-10,18-22,25-26,31-34,37H,11-14H2,1H3/t18-,19-,20-,21+,22-,25+,26?,27+,28+,29-,30+/m1/s1
|
| Chemical Name |
[(2R,3S,4S,5R,6S)-6-[[(2S,3R,5R,6R,8S)-2-(benzoyloxymethyl)-6-hydroxy-8-methyl-9,10-dioxatetracyclo[4.3.1.02,5.03,8]decan-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl 4-hydroxybenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6651 mL | 8.3254 mL | 16.6508 mL | |
| 5 mM | 0.3330 mL | 1.6651 mL | 3.3302 mL | |
| 10 mM | 0.1665 mL | 0.8325 mL | 1.6651 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.